Literature DB >> 2507748

Complex partial status epilepticus associated with cyclosporin A therapy.

R E Appleton1, K Farrell, P Teal, S A Hashimoto, P K Wong.   

Abstract

Significant neurotoxicity including seizures, encephalopathy and coma may complicate the use of cyclosporin A (CyA). Two patients are described, receiving CyA, who presented with abnormal behaviour, stupor, focal motor activity and were shown to be in complex partial status epilepticus (CPSE). Abnormalities of behaviour and/or stupor in patients receiving CyA may be a manifestation of CPSE. Patients receiving CyA who develop an encephalopathy should have electroencephalography performed at the time of the abnormal behaviour.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2507748      PMCID: PMC1031742          DOI: 10.1136/jnnp.52.9.1068

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  14 in total

1.  Cyclosporine-associated central nervous system toxicity after renal transplantation.

Authors:  H Wilczek; O Ringden; G Tyden
Journal:  Transplantation       Date:  1985-01       Impact factor: 4.939

2.  Prolonged partial complex status epilepticus: EEG and behavioral observations.

Authors:  J Engel; B I Ludwig; M Fetell
Journal:  Neurology       Date:  1978-09       Impact factor: 9.910

3.  Cyclosporin metabolites and central-nervous-system toxicity.

Authors:  U Kunzendorf; J Brockmöller; F Jochimsen; F Keller; G Walz; G Offermann
Journal:  Lancet       Date:  1988-05-28       Impact factor: 79.321

4.  Severe central-nervous-system toxicity associated with cyclosporin.

Authors:  J H Berden; A J Hoitsma; J L Merx; A Keyser
Journal:  Lancet       Date:  1985-01-26       Impact factor: 79.321

5.  Cyclosporin-associated fatal convulsions.

Authors:  T Velu; L Debusscher; P A Stryckmans
Journal:  Lancet       Date:  1985-01-26       Impact factor: 79.321

6.  Cyclosporine-associated central-nervous-system toxicity after allogeneic bone-marrow transplantation.

Authors:  K Atkinson; J Biggs; P Darveniza; J Boland; A Concannon; A Dodds
Journal:  N Engl J Med       Date:  1984-02-23       Impact factor: 91.245

7.  Generalised epileptic fits in renal transplant recipients given cyclosporin A.

Authors:  D Shah; P B Rylance; M E Rogerson; M Bewick; V Parsons
Journal:  Br Med J (Clin Res Ed)       Date:  1984-11-17

8.  Convulsions associated with cyclosporin A in transplant recipients.

Authors:  R J Polson; P R Powell-Jackson; R Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1985-03-30

9.  Convulsions associated with cyclosporin A in renal transplant recipients.

Authors:  M Beaman; S Parvin; P S Veitch; J Walls
Journal:  Br Med J (Clin Res Ed)       Date:  1985-01-12

10.  Association between cyclosporin neurotoxicity and hypomagnesaemia.

Authors:  C B Thompson; C H June; K M Sullivan; E D Thomas
Journal:  Lancet       Date:  1984-11-17       Impact factor: 79.321

View more
  4 in total

1.  Seizure treatment in transplant patients.

Authors:  Paul W Shepard; Erik K St Louis
Journal:  Curr Treat Options Neurol       Date:  2012-08       Impact factor: 3.598

2.  Central pontine myelinolysis following orthotopic liver transplant: association with cyclosporine toxicity.

Authors:  M H Kabeer; R S Filo; M L Milgrom; M D Pescovitz; S B Leapman; L Lumeng; R M Jindal
Journal:  Postgrad Med J       Date:  1995-04       Impact factor: 2.401

Review 3.  The pathophysiology of Sandimmune (cyclosporine) in man and animals.

Authors:  J Mason
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

Review 4.  Cognitive deficits related to major organ failure: the potential role of neuropsychological testing.

Authors:  M E Farmer
Journal:  Neuropsychol Rev       Date:  1994-06       Impact factor: 7.444

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.